FBRX · As filed with the SEC
Forte Biosciences cash flow statement, by fiscal year
The statement as Forte Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||
| Net loss | — | (35,478,000) | (31,476,000) | (13,879,000) | (21,708,000) | (46,487,000) | (63,516,000) | (48,955,000) |
| Net loss | (69,375,000) | — | — | — | — | — | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| In process research and development acquired | — | — | — | — | — | 30,885,000 | — | — |
| Depreciation expense | 64,000 | 39,000 | 9,000 | — | 36,000 | 54,000 | 843,000 | 625,000 |
| Noncash interest expense | — | — | — | — | — | — | 1,698,000 | 1,161,000 |
| Impairment of property and equipment | — | — | — | — | 61,000 | — | — | — |
| Accretion of debt discount on available-for-sale securities | — | — | (131,000) | — | — | — | — | — |
| Accretion of debt discount on available-for-sale securities | (237,000) | (158,000) | — | — | — | — | 161,000 | (248,000) |
| Loss on disposal of property and equipment | — | — | — | — | — | — | 1,212,000 | — |
| Gain on lease modification | — | — | — | — | — | — | (1,439,000) | — |
| Stock-based compensation expense | 6,258,000 | 3,095,000 | 3,284,000 | 4,015,000 | 4,214,000 | 956,000 | 8,060,000 | 6,870,000 |
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and other assets | (2,574,000) | (1,373,000) | (849,000) | 258,000 | 1,221,000 | (263,000) | 2,502,000 | (208,000) |
| Accounts payable | 5,543,000 | 3,021,000 | 271,000 | 207,000 | (294,000) | (369,000) | (58,000) | 1,260,000 |
| Accrued liabilities | 8,402,000 | 109,000 | 186,000 | 1,214,000 | (207,000) | (3,199,000) | (8,911,000) | 4,127,000 |
| Deferred license revenue | — | — | — | — | — | — | (36,000) | (36,000) |
| Deferred rent | — | — | — | — | — | — | — | 958,000 |
| Deferred grant funding | — | — | — | — | — | — | — | (23,000) |
| Other | — | — | — | — | — | — | 246,000 | — |
| Income taxes payable | 1,037,000 | — | — | — | — | — | — | — |
| Net cash used in operating activities | (50,882,000) | (30,745,000) | (28,706,000) | (8,185,000) | (16,677,000) | (18,423,000) | (59,238,000) | (34,469,000) |
| Cash flows from investing activities: | ||||||||
| Proceeds from the sale/maturity of marketable securities | — | — | — | — | — | — | 93,473,000 | 68,524,000 |
| Purchases of marketable securities | — | — | — | — | — | — | (51,163,000) | (70,746,000) |
| Cash and restricted cash acquired in reverse merger | — | — | — | — | — | 3,582,000 | — | — |
| Purchase of available-for-sale securities | 0 | (35,956,000) | (9,965,000) | — | — | — | — | — |
| Proceeds from maturity of available-for-sale securities | — | — | 10,100,000 | — | — | — | — | — |
| Proceeds from redemptions of short-term investments | 36,350,000 | — | — | — | — | — | — | — |
| Purchase of property and equipment | (116,000) | (37,000) | (88,000) | — | — | — | (428,000) | (1,968,000) |
| Proceeds from sale of property and equipment | — | — | — | — | — | — | 437,000 | — |
| Net cash provided by (used in) investing activities | 36,234,000 | (35,993,000) | 47,000 | — | — | 3,582,000 | 42,319,000 | (4,190,000) |
| Cash flows from financing activities: | ||||||||
| Proceeds from issuance of notes payable, net of issuance costs | — | — | — | — | — | — | — | 26,325,000 |
| Cash paid on extinguishment of debt | — | — | — | — | — | — | — | (8,631,000) |
| Principal payments on notes payable | — | — | — | — | — | — | (23,155,000) | (3,000,000) |
| Proceeds from issuance of common stock and pre-funded warrants | 75,000,000 | 53,000,000 | 24,728,000 | — | — | — | — | — |
| Payment of issuance costs associated with financings | (7,441,000) | (1,121,000) | — | — | (106,000) | (289,000) | — | — |
| Proceeds from exercise of employee stock options and issuance of common stock under ESPP | — | 14,000 | 16,000 | — | — | — | — | — |
| Proceeds from issuance of common stock upon exercise of underwriters' option | 1,779,000 | — | — | 7,229,000 | — | 66,699,000 | 551,000 | 661,000 |
| Proceeds from offering of common stock, net of issuance costs | — | — | — | — | — | — | 7,696,000 | 28,200,000 |
| Cash paid for deferred equity issuance costs | — | — | — | — | — | — | — | (16,000) |
| Proceeds from exercise of stock options | — | — | — | — | 62,000 | 257,000 | — | — |
| Proceeds from exercise of employee stock options and ESPP | — | — | — | 12,000 | — | — | — | — |
| Proceeds from issuance of common stock under ESPP | 18,000 | — | — | — | — | — | — | — |
| Proceeds from exercise of warrants and options | 34,000 | — | — | — | — | — | — | — |
| Taxes paid related to net share settlement of equity awards | (29,000) | (35,000) | (60,000) | — | — | — | — | — |
| Settlement of fractional shares paid in cash | 0 | (1,000) | — | — | — | — | — | — |
| Net cash provided by financing activities | 69,361,000 | 51,857,000 | 24,684,000 | 7,241,000 | (44,000) | 66,667,000 | (14,908,000) | 43,539,000 |
| Net increase (decrease) in cash and cash equivalents | — | — | — | — | — | — | — | 4,880,000 |
| Net increase (decrease) in cash and cash equivalents | 54,713,000 | (14,881,000) | (3,975,000) | (944,000) | (16,721,000) | 51,826,000 | (31,827,000) | — |
| Cash and cash equivalents, beginning of period | — | — | — | — | — | 8,986,000 | 40,813,000 | 35,933,000 |
| Cash and cash equivalents, end of period | — | — | — | — | — | — | 8,986,000 | 40,813,000 |
| Cash paid for interest | — | — | — | — | — | — | — | 1,522,000 |
| Cash paid for interest | — | — | — | — | — | — | 2,290,000 | — |
| Allowance for tenant improvements included in deferred rent | — | — | — | — | — | — | — | 1,243,000 |
| Cash and cash equivalents - beginning of year | 22,244,000 | 37,125,000 | 41,100,000 | 42,044,000 | 58,765,000 | 6,939,000 | — | — |
| Cash and cash equivalents - end of year | 76,957,000 | 22,244,000 | 37,125,000 | 41,100,000 | 42,044,000 | 58,765,000 | — | — |
| Conversion of preferred stock to common stock | — | — | — | — | — | 10,515,000 | — | — |
| Issuance of common stock to Tocagen shareholders | — | — | — | — | — | 31,809,000 | — | — |
| Supplemental disclosure of non-cash investing and financing activities: | ||||||||
| Unpaid issuance costs recorded in accounts payable and accrued liabilities | 41,000 | 2,316,000 | — | — | — | — | — | — |
| Purchase of property and equipment recorded in accrued liabilities | — | — | 30,000 | — | — | — | — | 178,000 |
| Fair value of common stock warrants issued in connection with notes payable | — | — | — | — | — | — | — | 479,000 |
| Deferred equity issuance costs in accounts payable and accrued liabilities | — | — | — | — | — | — | — | 310,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.